Quick Answer
Vanda Pharmaceuticals Inc. reported Research And Development Expense of $109.27 million for the year ending 2025.
- Vanda Pharmaceuticals Inc. showed an increase of +46.8% in Research And Development Expense from 2024 to 2025.
- This data is from Vanda Pharmaceuticals Inc.'s annual report (Form 10-K), filed with the SEC on February 12, 2026.
- XBRL data for this metric is available from 2009 to 2025 (17 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 17 years of available data (2009 to 2025), Vanda Pharmaceuticals Inc.'s Research And Development Expense has grown by 687.6%.
- Historical annual values: Fiscal year 2025: $109.27 million | Fiscal year 2024: $74.43 million | Fiscal year 2023: $76.82 million | Fiscal year 2022: $85.77 million | Fiscal year 2021: $75.36 million | Fiscal year 2020: $55.58 million | Fiscal year 2019: $48.65 million | Fiscal year 2018: $43.59 million | Fiscal year 2017: $38.55 million | Fiscal year 2016: $29.16 million | Fiscal year 2015: $29.15 million | Fiscal year 2014: $19.23 million | Fiscal year 2013: $28.50 million | Fiscal year 2012: $45.76 million | Fiscal year 2011: $29.00 million | Fiscal year 2010: $12.34 million | Fiscal year 2009: $13.87 million.
- Data sourced from SEC EDGAR public filings as of June 22, 2026.
Last verified: